Design of Gram-negative selective antimicrobial peptides

Biochemistry
S A Muhle, J P Tam

Abstract

Lipopolysaccharide (LPS), a major component of Gram-negative bacteria, signals bacterial invasion and triggers defensive host responses. However, excessive responses also lead to the serious pathophysiological consequence of septic shock. To develop Gram-negative selective compounds that can inhibit the effects of LPS-induced sepsis, we have designed constrained cyclic antimicrobial peptides based on a cystine-stabilized beta-stranded framework mimicking the putative LPS-binding sites of the LPS-binding protein family. Our prototype termed R4A, c(PACRCRAG-PARCRCAG), consists of an eight amino acid degenerated repeat constrained by a head-to-tail cyclic peptide backbone and two cross-bracing disulfides. NMR study of K4A, an R4A analogue with four Arg --> Lys replacements, confirmed the amphipathic design elements with four Lys on one face of the antiparallel beta-strand and two hydrophobic cystine pairs plus two Ala on the opposite face. K4A and R4A displayed moderate microbicidal potency and Gram-negative selectivity. However, R4A analogues with single or multiple replacements of Ala and Gly with Arg or bulky hydrophobic amino acids displayed increased potency and selectivity in both low- and high-salt conditions. Analogues R5L...Continue Reading

References

Feb 1, 1992·Current Opinion in Immunology·M Zasloff
Mar 21, 1991·Journal of Immunological Methods·R I LehrerP Eisenhauer
May 5, 1995·The Journal of Biological Chemistry·P S TobiasR J Ulevitch
Jan 1, 1995·Annual Review of Immunology·R J Ulevitch, P S Tobias
Jan 1, 1995·Annual Review of Immunology·H G Boman
Jan 1, 1995·Methods in Enzymology·E I SolomonS Pulver
Apr 1, 1995·Infection and Immunity·J W LarrickS C Wright
Jan 1, 1995·Annual Review of Microbiology·P Nicolas, A Mor
Dec 1, 1996·Infection and Immunity·M GoughN M Kelly
Jul 25, 1997·The Journal of Biological Chemistry·P S TobiasJ Weiss
Jul 31, 1998·Protein Science : a Publication of the Protein Society·J P Tam, Y A Lu
Feb 27, 1999·Current Opinion in Immunology·R I Lehrer, T Ganz
Aug 4, 1999·Proceedings of the National Academy of Sciences of the United States of America·J P TamK W Chiu
Jan 7, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·M G ScottM R Gold
Aug 18, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·N W SchröderR R Schumann
Sep 7, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·M G ScottR E Hancock

❮ Previous
Next ❯

Citations

Feb 16, 2002·European Journal of Biochemistry·James P TamJin-Long Yang
Aug 26, 2004·Antimicrobial Agents and Chemotherapy·V FrecerJ L Ding
Nov 11, 2011·International Journal of Molecular Sciences·Garry LavertyBrendan F Gilmore
Mar 19, 2011·Expert Opinion on Therapeutic Patents·Zhong-Cheng Song, Hai-Liang Zhu
Nov 3, 2006·Expert Review of Proteomics·Miriam M NgundiChris R Taitt
Nov 12, 2013·Expert Opinion on Biological Therapy·Jonathan D SteckbeckRonald C Montelaro
Dec 2, 2014·Biochimica Et Biophysica Acta·Wonyoung Lee, Dong Gun Lee
Jun 5, 2012·Journal of Bioscience and Bioengineering·Wataru AokiMitsuyoshi Ueda
Jun 15, 2011·Biotechnology Advances·Francesco Peri, Matteo Piazza
Feb 4, 2009·International Journal of Antimicrobial Agents·Jian HeRandal Eckert
Jun 1, 2014·Biochimica Et Biophysica Acta·Konstantin AndreevDavid Gidalevitz
Jul 31, 2009·Journal of Peptide Science : an Official Publication of the European Peptide Society·Ramamourthy GopalKyung-Soo Hahm
Jan 16, 2010·The FEBS Journal·Sylwia Rodziewicz-MotowidłoWojciech Kamysz
Sep 30, 2014·Chemical Biology & Drug Design·Garry LavertyBrendan F Gilmore
May 16, 2015·Journal of Molecular Graphics & Modelling·Eol Han, Hwankyu Lee
Mar 25, 2008·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Helle Krogh JohansenNiels Høiby
Nov 18, 2008·Biochimica Et Biophysica Acta·Lanlan YuThorsten Wohland
Mar 2, 2005·Biochimica Et Biophysica Acta·Howard N HunterHans J Vogel
Aug 9, 2016·Advanced Drug Delivery Reviews·Danir Fanisovich Bayramov, Jennifer Ann Neff
Jan 26, 2017·Frontiers in Microbiology·Beatriz T MeneguettiOctávio L Franco
Nov 28, 2013·Pharmaceuticals·Wataru Aoki, Mitsuyoshi Ueda
Feb 9, 2017·Antimicrobial Agents and Chemotherapy·Cheng-Foh LeShamala Devi Sekaran
Oct 1, 2009·Chemistry : a European Journal·Karen LienkampGregory N Tew
Apr 25, 2007·The Journal of Biological Chemistry·Guozhang ZouWuyuan Lu
Jan 27, 2021·Journal of Peptide Science : an Official Publication of the European Peptide Society·Zhou Ye, Conrado Aparicio
Jan 10, 2021·International Journal of Molecular Sciences·Giovanna BatoniSemih Esin
Mar 4, 2020·Biochimica Et Biophysica Acta. Biomembranes·Mauricio AriasHans J Vogel
Jun 7, 2017·Biochimica Et Biophysica Acta. Biomembranes·A Rice, J Wereszczynski
Jan 19, 2020·Biochimica Et Biophysica Acta. Biomembranes·Gopal PanditSunanda Chatterjee
Mar 20, 2010·The Journal of Physical Chemistry. B·Sisir DebnathPrasanta Kumar Das

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.